Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1979 Jul;25(1):273–278. doi: 10.1128/iai.25.1.273-278.1979

Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide.

F Kireszenbaum, R W Ferraresi
PMCID: PMC414448  PMID: 113344

Abstract

N-acetylmuramyl-L-alanyl-D-isoglutamine (muramyl dipeptide [MDP]) enhanced resistance against Trypanosoma cruzi infection in mice. This effect was evidenced by significant reductions in both parasitemias and mortality rates and increased survival time in MDP-treated animals compared with untreated infected mice. MDP effectively augmented host resistance when administered in any one of the following ways: (i) continuous subcutaneous release from an osmotic minipump for a 7-day period starting 2 days before infection; (ii) as a single dose of 0.5 mg injected intraperitoneally 48 h before infection; or (iii) injected intraperitoneally at 48-h intervals during the first 16 days after infection. CBA/J mice, which exhibit very low, insignificant augmentation of reticuloendothelial activity by MDP but are susceptible to its adjuvant effect, failed to manifest enhancement of resistance to T. cruzi infection when treated with MDP under regimens that cause increased resistance in other mouse strains. These results suggest that MDP enhances resistance against T. cruzi infection by stimulating the activity of the phagocytic cells of the host. Adjuvant effect appears to play either a less significant role or no relevant role, except when MDP is administered repeatedly after infection.

Full text

PDF
273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Audibert F., Chedid L., Hannoun C. Augmentation de la réponse immunitaire au vaccin grippal par un glycopeptide synthétique adjuvant (N-acétyl muramyl-L-alanyl-D-isoglutamine). C R Acad Sci Hebd Seances Acad Sci D. 1977 Sep 12;285(4):467–470. [PubMed] [Google Scholar]
  2. Audibert F., Chédid L., Lefrancier P., Choay J. Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell Immunol. 1976 Feb;21(2):243–249. doi: 10.1016/0008-8749(76)90053-8. [DOI] [PubMed] [Google Scholar]
  3. Chedid L., Audibert F., Lefrancier P., Choay J., Lederer E. Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2472–2475. doi: 10.1073/pnas.73.7.2472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Damais C., Parant M., Chedid L. Nonspecific activation of murine spleen cells in vitro by a synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine). Cell Immunol. 1977 Nov;34(1):49–56. doi: 10.1016/0008-8749(77)90228-3. [DOI] [PubMed] [Google Scholar]
  6. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  7. Emori K., Tanaka A. Granuloma formation by synthetic bacterial cell wall fragment: muramyl dipeptide. Infect Immun. 1978 Feb;19(2):613–620. doi: 10.1128/iai.19.2.613-620.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Igarashi T., Okada M., Azuma I., Yamamura Y. Adjuvant activity of synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds on cell-mediated cytotoxicity in syngeneic mice. Cell Immunol. 1977 Dec;34(2):270–278. doi: 10.1016/0008-8749(77)90249-0. [DOI] [PubMed] [Google Scholar]
  9. Juy D., Chedid L. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci U S A. 1975 Oct;72(10):4105–4109. doi: 10.1073/pnas.72.10.4105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kierszenbaum F. Enhancement of resistance and suppression of immunization against experimental Trypanosoma cruzi infection by Corynebacterium parvum. Infect Immun. 1975 Nov;12(5):1227–1229. doi: 10.1128/iai.12.5.1227-1229.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kierszenbaum F., Knecht E., Budzko D. B., Pizzimenti M. C. Phagocytosis: a defense mechanism against infection with Trypanosoma cruzi. J Immunol. 1974 May;112(5):1839–1844. [PubMed] [Google Scholar]
  12. Kierszenbaum F., Saavedra L. E. The effects of bacterial endotoxin on the infection of mice with Trypanosoma cruzi. J Protozool. 1972 Nov;19(4):655–657. doi: 10.1111/j.1550-7408.1972.tb03552.x. [DOI] [PubMed] [Google Scholar]
  13. Kotani S., Narita T., Stewart-Tull D. E., Shimono T., Watanabe Y. Immunoadjuvant activities of cell walls and their water-soluble fractions prepared from various gram-positive bacteria. Biken J. 1975 Jun;18(2):77–92. [PubMed] [Google Scholar]
  14. Kotani S., Watanabe Y., Shimono T., Kinoshita F., Narita T. Immunoadjuvant activities of peptidoglycan subunits from the cell walls of Staphyloccus aureus and Lactobacillus plantarum. Biken J. 1975 Jun;18(2):93–103. [PubMed] [Google Scholar]
  15. Löwy I., Bona C., Chedid L. Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell Immunol. 1977 Mar 1;29(1):195–199. doi: 10.1016/0008-8749(77)90288-x. [DOI] [PubMed] [Google Scholar]
  16. Specter S., Friedman H., Chedid L. Dissociation between the adjuvant vs mitogenic activity of a synthetic muramyl dipeptide for murine splenocytes. Proc Soc Exp Biol Med. 1977 Jul;155(3):349–352. doi: 10.3181/00379727-155-39804. [DOI] [PubMed] [Google Scholar]
  17. Sugimoto M., Germain R. N., Chedid L., Benacerraf B. Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP). J Immunol. 1978 Mar;120(3):980–982. [PubMed] [Google Scholar]
  18. Tanaka A., Nagao S., Saito R., Kotani S., Kusumoto S., Shiba T. Correlation of stereochemically specific structure in muramyl dipeptide between macrophage activation and adjuvant activity. Biochem Biophys Res Commun. 1977 Jul 25;77(2):621–627. doi: 10.1016/s0006-291x(77)80024-7. [DOI] [PubMed] [Google Scholar]
  19. Yamamoto Y., Nagao S., Tanaka A., Koga T., Onoue K. Inhibition of macrophage migration by synthetic muramyl dipeptide. Biochem Biophys Res Commun. 1978 Feb 28;80(4):923–928. doi: 10.1016/0006-291x(78)91333-5. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES